Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -7.58 is 156% below its 5-year average of -2.96, near the low end of its 5-year range (-7.58–0.00).
As of the fiscal period ended Tuesday, June 30, 2026. 16.98% below its 12-month average of -6.48.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -7.58.
DEBT TO EQUITY RATIO
-7.58
DEBT TO EQUITY RATIO AVG TTM
-6.48
DEBT TO EQUITY RATIO AVG 3Y
-3.92
DEBT TO EQUITY RATIO AVG 5Y
-2.96
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-16.98%
CURRENT VS 3Y AVG
-93.29%
CURRENT VS 5Y AVG
-156.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.17
median of 348 covered companies
CURRENT VS SECTOR MEDIAN
-4695.12%
vs the sector median at left
Market Cap
$2.06B
Debt to Equity Ratio
N/A
TTM Avg
2.21
3Y Avg
2.21
5Y Avg
2.21
Market Cap
$2.05B
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.07
Market Cap
$2.11B
Debt to Equity Ratio
0.09
TTM Avg
0.24
3Y Avg
0.25
5Y Avg
0.32
Market Cap
$2.02B
Debt to Equity Ratio
0.10
TTM Avg
0.17
3Y Avg
0.15
5Y Avg
0.11
Market Cap
$2.01B
Debt to Equity Ratio
2.13
TTM Avg
1.43
3Y Avg
0.96
5Y Avg
0.78
Market Cap
$2.17B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.07B | -7.58 | -6.48 | -3.92 | -2.96 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | N/A | 2.21 | 2.21 | 2.21 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 0.04 | 0.04 | 0.04 | 0.07 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 0.09 | 0.24 | 0.25 | 0.32 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 0.10 | 0.17 | 0.15 | 0.11 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 2.13 | 1.43 | 0.96 | 0.78 |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 0.08 | 0.59 | 0.64 | 0.60 |
| Azenta, Inc. (AZTA)vs › | $1.97B | 0.04 | 0.05 | 0.03 | 0.05 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | 0.01 | 0.01 | 0.01 | 0.01 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | 12.20 | 7.74 | 8.64 | 5.54 |
Debt/Equity
-7.58
Current Ratio
1.65
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -7.58 |
| 2026-03-31 | -5.16 |
| 2025-12-31 | -5.09 |
| 2025-09-30 | -7.25 |
| 2025-06-30 | -7.32 |
| 2025-03-31 | -4.06 |
| 2024-12-31 | -2.88 |
| 2024-09-30 | -3.43 |
| 2024-06-30 | -1.96 |
| 2024-03-31 | -1.67 |
| 2023-12-31 | -1.15 |
| 2023-08-31 | -1.54 |
| 2023-06-30 | -1.89 |
| 2023-03-31 | -1.27 |
| 2022-12-31 | -1.43 |
| 2022-09-30 | -2.30 |
| 2022-06-30 | -2.30 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | -3.86 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | -0.78 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | -0.65 |
| 2020-03-31 | -0.65 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
